{
  "id": "6025e3a71cb411341a0000bc",
  "type": "list",
  "question": "Which mutations are inhibited by Ripretinib?",
  "ideal_answer": "Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33948116",
    "http://www.ncbi.nlm.nih.gov/pubmed/32578014",
    "http://www.ncbi.nlm.nih.gov/pubmed/33473249",
    "http://www.ncbi.nlm.nih.gov/pubmed/31755321",
    "http://www.ncbi.nlm.nih.gov/pubmed/32859585",
    "http://www.ncbi.nlm.nih.gov/pubmed/32511981",
    "http://www.ncbi.nlm.nih.gov/pubmed/34503977",
    "http://www.ncbi.nlm.nih.gov/pubmed/34391056",
    "http://www.ncbi.nlm.nih.gov/pubmed/33947686",
    "http://www.ncbi.nlm.nih.gov/pubmed/31033566",
    "http://www.ncbi.nlm.nih.gov/pubmed/33876372",
    "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
    "http://www.ncbi.nlm.nih.gov/pubmed/32804590"
  ],
  "snippets": [
    {
      "text": "Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804590",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The KIT/PDGFRA Inhibitor Ripretinib Shows Signs of Activity in GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32859585",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Both avapritinib and ripretinib are more potent and more specific against various KIT and PDGFRA mutations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31033566",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31755321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib inhibits KIT and PDGFRA kinase, including wild-type, primary and secondary mutations, as well as other kinases, such as PDGFRB, TIE2, VEGFR2 and BRAF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32578014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (QINLOCK\u2122) is a novel type II tyrosine switch control inhibitor being developed by Deciphera Pharmaceuticals for the treatment of KIT proto-oncogene receptor tyrosine kinase (KIT)-driven and/or platelet derived growth factor receptor A (PDGFRA)-driven cancers, including gastrointestinal stromal tumour (GIST).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32578014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ".0001; exon 9, P = 0.0023; exon 13, P < 0.0001; exon 17, P < 0.0001). Among patients with wild-type KIT/PDGFRA by tumor tissue, PFS ranged from 2 to 23 months for ripretinib versus 0.9 to 10.1 months for placebo.CONCLUSIONS: Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripretinib inhibits a broad rang",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34503977",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib is a novel switch-pocket inhibitor with broad activity against KIT and PDGFRA oncoproteins and has recently demonstrated antitumoral activity across phase I to phase III clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33473249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.PATIENTS AND METHODS: This first-in-human, to our kn",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804590",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Ripretinib is a switch-control tyrosine kinase inhibitor that broadly inhibits KIT and platelet-derived growth factor receptor \u03b1 kinase signalling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34391056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " possible. Ripretinib - a novel switch-control TKI - inhibits many of the most common primary and secondary activating KIT and PDGFRA mutants involved in GIST progression through a dual mechanis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33948116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Rip",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31085175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "y, United States Federal and Drug Administration (FDA) approved two new tyrosine kinase inhibitors for the treatment of heavily pretreated advanced/unresectable GIST including avapritinib (a selective inhibitor for PDGFRA exon 18 mutation including D842V mutations) and ripretinib (a broad-spectrum kinase inhibitor of c-Kit and PDGFRA). In this ar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33876372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31755321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib potently inhibits a broad spectrum of primary and drug-resistant KIT/PDGFRA mutants and is approved by the FDA for the treatment of adult patients with advanced GIST who have received previous treatment with 3 or more kinase inhibitors, including imatinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ripretinib - a novel switch-control TKI - inhibits many of the most common primary and secondary activating KIT and PDGFRA mutants involved in GIST progression through a dual mechanism of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33948116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n 13, P < 0.0001; exon 17, P < 0.0001). Among patients with wild-type KIT/PDGFRA by tumor tissue, PFS ranged from 2 to 23 months for ripretinib versus 0.9 to 10.1 months for placebo.CONCLUSIONS: Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripretinib inhibits a broad range of KIT/PDGFRA mutations in patients with advanced GIST",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34503977",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "al tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours.METHODS: In this double-blind, randomised, placebo-controlled, phase 3 study, we enrolled adult patients in 29 specialised hospi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "roteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.PATIENTS AND METHODS: This first-in-human, to our knowledge, phase I study of ripretinib (ClinicalTrials.gov identifier: NCT02571036) included a dose-escalation phase and subsequent expansion phase at the re",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804590",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "KIT, PDGFRA"
}